The epidemiology of venous thromboembolism

Heit, John A.; Spencer, Frederick A.; White, Richard

doi:10.1007/s11239-015-1311-6

Cited by 993 publications

(833 citation statements)

References 205 publications

(230 reference statements)

Supporting

Mentioning

748

Contrasting

Unclassified

Order By: Relevance

“…6 In patients after the first incident of VTE, the prevalence of AT, PC, and PS deficiencies is estimated at 0.5% to 4.9%, 3%, and 2% to 12%, respectively. 2,3,7 Evidence linking natural anticoagulant deficiencies with arterial thromboembolism, mostly ischemic stroke, is conflicting and largely derived from case reports. 2,8,9 AT is the main endogenous anticoagulant serpin (serine -protease inhibitor) that primarily inactivates thrombin and activated factor (F) X.…”

Section: Original Articlementioning

confidence: 99%

Genetic characterization of antithrombin, protein C and protein S deficiencies in Polish patients

Wypasek¹,

Corral²,

Alhenc‐Gelas³

et al. 2017

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Section: Original Articlementioning

confidence: 99%

Genetic characterization of antithrombin, protein C and protein S deficiencies in Polish patients

Wypasek¹,

Corral²,

Alhenc‐Gelas³

et al. 2017

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

“…The two major subtypes of VTE are deep vein thrombosis (DVT) and pulmonary embolism (PE). Patients who have had their first VTE episode have increased risk of recurrence,5, 6, 7, 8, 9 with the risk being highest in the first few months after the initial episode and remaining high through the first year 10. About a quarter of patients will have a recurrent episode within 5 years of their initial VTE episode and 30% are expected to have a recurrent episode within 10 years 10…”

Section: Introductionmentioning

confidence: 99%

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism

Berger

Seheult

Laliberté

et al. 2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Essentials Clinical trials demonstrated the gain of extended anticoagulation among patients with VTE.In a real‐world setting, we evaluated outcomes of extended rivaroxaban use for unprovoked VTE.Extended rivaroxaban treatment lowered the risk of recurrent VTE among unprovoked VTE patients.Extended rivaroxaban treatment was not associated with increased risk of major bleeding. BackgroundRandomized trial data demonstrate the gain of extended duration anticoagulation in patients with venous thromboembolic events (VTE); however, real‐world data are limited.ObjectivesAssess the risk of recurrent VTE and major bleeding in a real‐world setting of patients who experienced unprovoked VTE and received extended treatment with rivaroxaban.Methods US claims databases (February 2011–April 2015) were used in this retrospective study. The study population included adult patients initiated on rivaroxaban within 7 days after their first unprovoked VTE (ie, deep vein thrombosis, pulmonary embolism) and received ≥3 months continuous rivaroxaban treatment (index date: end of 3‐month treatment). Patients who were treated beyond 3 months formed the continued cohort and the remainder formed the discontinued cohort (ie, discontinued at 3 months). Adjusted Kaplan‐Meier rates for recurrent VTE and major bleeding events were compared between cohorts with confounders being controlled through a propensity score weighting approach.ResultsPatients in the continued cohort (N = 3763) had significantly lower rates of recurrent VTE than those who discontinued (N = 1051): 0.57% vs 1.19% (P = .042), 1.07% vs 2.10% (P = .017), and 1.45% vs 2.60% (P = .023) at 3, 6, and 12 months, respectively. No significant differences in the rate of major bleeding were observed between cohorts. A sensitivity analysis among unprovoked VTE patients receiving rivaroxaban for ≥6 months showed similar results.ConclusionsContinued rivaroxaban treatment beyond an initial 3‐ or 6‐month treatment period significantly lowered the risk of recurrent VTE without a significant increase of major bleeding, compared to treatment discontinued at 3 or 6 months.

show abstract

“…VTE is considered a serious public health problem due to its high morbidity and mortality rate (Heit, Spencer, & White, 2016). In 2007 this pathology was found to be responsible for about 12% of deaths in Europe (Amaral, & Tavares, 2013) and direct healthcare costs related to VTE in the European Union per year range from 1.5 to 13.2 (Behravesh, Hoang, Nanda, Wallace, Sheth, Deipolyi, & Oklu, 2017).…”

Section: Introductionmentioning

confidence: 99%

Preventive Measures Of Venous Thromboembolism In The Hospitalized Patient: An Integrative Literature Review

Albuquerque¹,

Costa²,

Martins³

et al. 2017

European Proceedings of Social and Behavioural Sciences

View full text Add to dashboard Cite

Venous thromboembolism (VTE) includes two closely associated clinical conditions: deep vein thrombosis (DTV) and its main acute complication, pulmonary embolism (PE). In the hospital setting, venous thromboembolism is a concern because of its high prevalence rate. It is estimated that one in twenty inpatients is at risk of pulmonary embolism, if adequate preventive measures are not applied.These may or may not be pharmacological. In this context, the objective of this study is to identify the non-pharmacological measures recommended to prevent venous thromboembolism in inpatients. An integrative literature review was performed using the PI[C]OD method by searching the following databases: EBSCO host, PubMed, JBI, PEDro, Elsevier-ClinicalKey, Scielo and Google Academic studies published in the períod 2006-2016. From the research were included five articles that met the inclusion criteria. The results of the review found that effective mechanical methods comprised graduated compression stockings and intermittent pneumatic compression devices while for nursing care early mobilization and ambulation were identified as preventive measures of VTE. The studies suggest several benefits of using non-pharmacological measures to prevent venous thromboembolism. The differentiated intervention of the nurse specialist in rehabilitation integrated in the multidisciplinary team can be an added value in the adequacy of these measures.

show abstract

The epidemiology of venous thromboembolism

Cited by 993 publications

References 205 publications

Genetic characterization of antithrombin, protein C and protein S deficiencies in Polish patients

Genetic characterization of antithrombin, protein C and protein S deficiencies in Polish patients

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism

Preventive Measures Of Venous Thromboembolism In The Hospitalized Patient: An Integrative Literature Review

Contact Info

Product

Resources

About